Description
Confirmed survival benefit of combined BRAF and MEK inhibition in advanced BRAF mutant melanoma
Article: Confirmed survival benefit of combined BRAF and MEK inhibition in advanced BRAF mutant melanoma
€3.03
Related products
-
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart
